特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
963472

マイクロバイオーム治療薬:世界市場

Microbiome Therapeutics: Global Markets

出版日: | 発行: BCC Research | ページ情報: 英文 167 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.45円
マイクロバイオーム治療薬:世界市場
出版日: 2020年10月06日
発行: BCC Research
ページ情報: 英文 167 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のマイクロバイオーム治療薬市場は、2021年の1億4,170万米ドルから、2026年までに13億米ドルまで拡大し、2021年~2026年のCAGRで56.4%の成長が予測されています。GIT疾患市場は、2021年の8,790万米ドルから、2026年までに2億2,200万米ドルまで拡大し、2021年~2026年のCAGRで20.4%の成長が予測されています。感染症市場は、2021年の5,380万米ドルから、2026年までに1億9,180万米ドルまで拡大し、2021年~2026年のCAGRで28.9%の成長が予測されています。

当レポートでは、世界のマイクロバイオーム治療薬市場について調査分析し、現在の市場状況、動向、5年間の成長予測について、体系的な情報を提供しています。

目次

第1章 イントロダクション

第2章 サマリーとハイライト

第3章 市場と技術の背景

  • ヒトマイクロバイオーム
    • さまざまなヒトのマイクロバイオーム
    • マイクロバイオームとヒトの健康と疾患
    • マイクロバイオーム研究を支援する技術
    • マイクロバイオーム研究プロジェクト
  • マイクロバイオーム治療薬
    • マイクロバイオーム治療薬の開発の戦略
    • マイクロバイオーム治療薬の疾患分野
    • マイクロバイオーム治療薬の規制状況

第4章 市場内訳:技術タイプ別

  • 市場:マイクロバイオーム戦略タイプ別
    • 市場概要
    • 相加マイクロバイオーム治療薬
    • 調整マイクロバイオーム治療薬
    • 減法マイクロバイオーム治療薬

第5章 市場内訳:適応別

  • 市場:疾患タイプ別
    • 市場概要
    • 市場収益
    • 市場シェア
    • 感染症
    • 胃腸(GIT)疾患
    • 代謝性疾患
    • がん
    • 脳腸軸疾患
    • その他
  • 市場:地域別
    • 市場シェア

第6章 業界構造

  • マイクロバイオーム治療薬への投資
  • コラボレーション・パートナーシップ
  • ライセンシング・製造契約
  • M&A
  • マイクロバイオーム治療薬市場の主要企業
  • 主要考察

第7章 特許分析

  • 特許分析
    • 特許:年別
    • 特許:タイプ別
    • 特許:疾患タイプ別
    • 特許:企業別
    • 特許:国別
    • 特許:譲受人別

第8章 臨床試験分析

  • 臨床試験分析:疾患カテゴリー別
    • 臨床試験のシェア
  • 臨床試験分析:治療戦略別
    • 臨床試験のシェア
  • 臨床試験分析:企業別
    • 臨床試験のシェア
  • 創薬・前臨床開発におけるマイクロバイオーム治療薬
  • フェーズ3におけるマイクロバイオーム治療薬の臨床試験

第9章 市場機会の分析

  • SWOT分析

第10章 企業プロファイル

  • 4D PHARMA
  • AO BIOME LLC
  • ASSEMBLY BIOSCIENCES INC.
  • ARMATA PHARMACEUTICALS
  • AZITRA INC.
  • BIOMICA
  • BIOMX
  • CHAIN BIOTECHNOLOGY LTD.
  • ELIGO BIOSCIENCE SAS
  • ENTEROME SA
  • EVELO BIOSCIENCES
  • FINCH THERAPEUTICS GROUP INC.
  • INTRALYTIX INC.
  • KALEIDO BIOSCIENCES
  • KINTAI THERAPEUTICS INC.
  • LNC THERAPEUTICS INC.
  • MAAT PHARMA
  • OSEL INC.
  • PYLUM BIOSCIENES INC.
  • QUORUM INNOVATIONS LLC
  • REBIOTIX INC. (ACQUIRED BY FERRING PHARMACEUTICALS)
  • SECOND GENOME
  • SERES THERAPEUTICS INC.
  • SFA THERAPEUTICS INC.
  • SYNLOGIC
  • SYNTHETIC BIOLOGICS INC.
  • VEDANTA BIOSCIENCES INC.

第11章 付録:略語

図表

List of Tables

  • Summary Table: Global Market for Microbiome Therapeutics, by Disease Type, Through 2026
    • Table 1: Technologies for Microbiome Research
    • Table 2: Dysbiosis in Microbiome
    • Table 3: Leading Pharmaceuticals in Microbiome Therapeutics Partnerships
    • Table 4: Global Market for Microbiome Therapeutics, by Strategy Type, Through 2026
    • Table 5: Global Market Shares of Microbiome Therapeutics, by Strategy Type, 2024
    • Table 6: LBPs in Microbiome Therapeutics
    • Table 7: Global Market for Additive Microbiome Therapeutics, by Type, Through 2026
    • Table 8: Global Market Shares of Additive Microbiome Therapeutics, by Type, 2024
    • Table 9: Modulatory Microbiome Therapeutics
    • Table 10: Global Market for Modulatory Microbiome Therapeutics, by Type, Through 2026
    • Table 11: Global Market Shares of Modulatory Microbiome Therapeutics, by Type, 2024
    • Table 12: Global Market for Subtractive Microbiome Therapeutics, by Type, Through 2026
    • Table 13: Global Market Shares of Subtractive Microbiome Therapeutics, by Type, 2024
    • Table 14: R&D Expenditures in Microbiome Therapeutics, by Company, 2017-2019
    • Table 15: Global Market for Microbiome Therapeutics, by Disease Type, Through 2026
    • Table 16: Global Market Shares of Microbiome Therapeutics, by Disease Type, 2024
    • Table 17: Microbiome Therapeutics in Infections
    • Table 18: Global Market for Microbiome Therapeutics for Infections, by Region, Through 2026
    • Table 19: Microbiome Therapeutics in GIT Diseases
    • Table 20: Global Market for Microbiome Therapeutics for GIT Diseases, by Region Through 2026
    • Table 21: Microbiome Therapeutics in Metabolic Diseases
    • Table 22: Global Market for Microbiome Therapeutics for Metabolic Diseases, by Region, Through 2026
    • Table 23: Microbiome Therapeutics in Cancer
    • Table 24: Global Market for Microbiome Therapeutics for Cancer, by Region, Through 2026
    • Table 25: Microbiome Therapeutics in Gut-Brain Axis Diseases
    • Table 26: Global Market for Microbiome Therapeutics for Gut-Brain Axis Diseases, by Region, Through 2026
    • Table 27: Microbiome Therapeutics in Other Diseases
    • Table 28: Global Market for Microbiome Therapeutics for Other Diseases, by Region, Through 2026
    • Table 29: Global Market for Microbiome Therapeutics, by Region, Through 2026
    • Table 30: Global Market Shares of Microbiome Therapeutics, by Region, 2024
    • Table 31: Historical Funding Activity in Microbiome Therapeutics, 2015 and 2016
    • Table 32: Public Funding in Microbiome Therapeutics, 2018-August 2020
    • Table 33: Venture Funding in Microbiome Therapeutics, 2017-August 2020
    • Table 34: Collaborations and Partnerships in the Microbiome Therapeutics Market, 2017-August 2020
    • Table 35: Licensing and Manufacturing Agreements in the Microbiome Therapeutics Market, 2017-August 2020
    • Table 36: Leading Developers of Additive Microbiome Therapeutics, 2019
    • Table 37: Leading Developers of Modulatory Microbiome Therapeutics, 2019
    • Table 38: Leading Developers of Subtractive Microbiome Therapeutics, 2019
    • Table 39: Patents Issued for Microbiome Therapeutics, by Year, 2017-August 2020
    • Table 40: Patents Issued for Microbiome Therapeutics, by Type, 2017-August 2020
    • Table 41: Patents Issued for Microbiome Therapeutics, by Disease Type, 2017-August 2020
    • Table 42: Patents Issued for Microbiome Therapeutics, by Company, 2017-August 2020
    • Table 43: Patents Issued for Microbiome Therapeutics, by Country, 2017-August 2020
    • Table 44: Patents Issued for Microbiome Therapeutics, by Assignee, 2017-August 2020
    • Table 45: Clinical Trials in Microbiome Therapeutics, by Disease Type, August 2020
    • Table 46: Share of Clinical Trials in Microbiome Therapeutics, by Disease Type, August 2020
    • Table 47: Clinical Trials in Microbiome Therapeutics, by Treatment Strategy
    • Table 48: Share of Clinical Trials in Microbiome Therapeutics, by Treatment Strategy
    • Table 49: Clinical Trials in Microbiome Therapeutics, by Company
    • Table 50: Share of Clinical Trials in Microbiome Therapeutics, by Top 10 Companies
    • Table 51: Microbiome Therapeutics in Discovery and Preclinical Development
    • Table 52: Microbiome Therapeutics Clinical Trials in Phase 3
    • Table 53: 4D Pharma's Pipeline
    • Table 54: AO Biome's Pipeline
    • Table 55: Assembly Biosciences' Pipeline
    • Table 56: Armata Pharmaceuticals' Pipeline
    • Table 57: Azitra's Pipeline
    • Table 58: Biomica's Pipeline
    • Table 59: BiomX's Pipeline
    • Table 60: Chain Biotechnology's Pipeline
    • Table 61: Enterome's Pipeline
    • Table 62: Evelo Biosciences' Pipeline
    • Table 63: Finch Therapeutics' Pipeline
    • Table 64: Intralytix's Pipeline
    • Table 65: Kaleido Biosciences' Pipeline
    • Table 66: Kintai Therapeutics' Pipeline
    • Table 67: LNC Therapeutics' Pipeline
    • Table 68: MaaT Pharma's Pipeline
    • Table 69: Osel's Pipeline
    • Table 70: Quorum Innovations' Pipeline
    • Table 71: Rebiotix's Pipeline
    • Table 72: Second Genome's Pipeline
    • Table 73: Seres Therapeutics' Pipeline
    • Table 74: SFA Therapeutics' Pipeline
    • Table 75: Synlogic's Pipeline
    • Table 76: Synthetic Biologics' Pipeline
    • Table 77: Vedanta Biosciences' Pipeline
    • Table 78: Acronyms Used in Microbiome Therapeutics

List of Figures

  • Summary Figure: Global Market for Microbiome Therapeutics, by Disease Type, 2021-2026
    • Figure 1: Differences in Human Genome and Microbiome
    • Figure 2: Bacterial Distribution, by Body Site
    • Figure 3: Essential Functions of Human Microbiome
    • Figure 4: Dysbiosis and Human Health
    • Figure 5: Summary of NIH Funding for Microbiome Research, 2012-2016
    • Figure 6: Global Market for Microbiome Therapeutics, by Strategy Type, 2021-2026
    • Figure 7: Global Market Shares of Microbiome Therapeutics, by Strategy Type, 2024
    • Figure 8: Global Market for Additive Microbiome Therapeutics, by Type, 2021-2026
    • Figure 9: Global Market Shares of Additive Microbiome Therapeutics, by Type, 2024
    • Figure 10: Global Market for Modulatory Microbiome Therapeutics, by Type, 2021-2026
    • Figure 11: Global Market Shares of Modulatory Microbiome Therapeutics, by Type, 2024
    • Figure 12: Global Market for Subtractive Microbiome Therapeutics, by Type, 2021-2026
    • Figure 13: Global Market Shares of Subtractive Microbiome Therapeutics, by Type, 2024
    • Figure 14: Global Market for Microbiome Therapeutics, by Disease Type, 2021-2026
    • Figure 15: Global Market Shares of Microbiome Therapeutics, by Disease Type, 2024
    • Figure 16: Global Market for Microbiome Therapeutics for Infections, by Region, 2021-2026
    • Figure 17: Global Market for Microbiome Therapeutics for GIT Diseases, by Region, 2021-2026
    • Figure 18: Global Market for Microbiome Therapeutics for Metabolic Diseases, by Region, 2021-2026
    • Figure 19: Global Market for Microbiome Therapeutics for Cancer, by Region, 2021-2026
    • Figure 20: Global Market for Microbiome Therapeutics for Gut-Brain Axis Diseases, by Region, 2021-2026
    • Figure 21: Global Market for Microbiome Therapeutics for Other Diseases, by Region, 2021-2026
    • Figure 22: Global Market for Microbiome Therapeutics, by Region, 2021-2026
    • Figure 23: Global Market Shares of Microbiome Therapeutics, by Region, 2024
    • Figure 24: Patents Issued for Microbiome Therapeutics, by Year, 2017-August 2020
    • Figure 25: Patents Issued for Microbiome Therapeutics, by Type, 2017-August 2020
    • Figure 26: Patents Issued for Microbiome Therapeutics, by Disease Type, 2017-August 2020
    • Figure 27: Patents Issued for Microbiome Therapeutics, by Company, 2017-August 2020
    • Figure 28: Patents Issued for Microbiome Therapeutics, by Country, 2017-August 2020
    • Figure 29: Patents Issued for Microbiome Therapeutics, by Assignee, 2017-August 2020
    • Figure 30: Share of Clinical Trials in Microbiome Therapeutics, by Disease Type, August 2020
    • Figure 31: Share of Clinical Trials in Microbiome Therapeutics, by Treatment Strategy
    • Figure 32: Share of Clinical Trials in Microbiome Therapeutics, by Top 10 Companies
    • Figure 33: SWOT Analysis of the Microbiome Therapeutics Market
目次
Product Code: BIO205A

Highlights:

The global market for microbiome therapeutics should grow from $141.7 million in 2021 to $1.3 billion by 2026, at compound annual growth rate (CAGR) of 56.4% for the period of 2021-2026.

GIT diseases market for microbiome therapeutics should grow from $87.9 million in 2021 to $222.0 million by 2026, at a CAGR of 20.4% for the period of 2021-2026.

Infections diseases market for microbiome therapeutics should grow from $53.8 million in 2021 to $191.8 million by 2026, at a CAGR of 28.9% for the period of 2021-2026.

Report Scope:

BCC Research's new report, "Microbiome Therapeutics: Global Markets," provides a comprehensive analysis of the microbiome therapeutics market in global context, including market forecasts and sales through 2025. The report analyzes the market by segmenting it into the various types of microbiome therapeutics, based on the strategies used for treatment: additive (fecal matter transplants or FMTs, live biotherapeutic products or LBPs), modulatory (postbiotics, prebiotics) and subtractive microbiome therapeutics (phages and antimicrobials). This study surveys the microbiome therapeutics market by application or disease segments: infectious diseases, metabolic diseases, cancer, gut-brain axis and others. The market is also assessed in the following geographic regions: North America, Europe and emerging markets. Emerging markets include countries like India, China, Korea, Taiwan, Africa, Australia, New Zealand, Canada and Latin America.

The report features leading clinical trials indicating the status and phase of development. New developments and patents are boosting the growth of this market in the global context.

The new BCC report provides comprehensive profiles of market players in the industry. The industry structure chapter focuses on the changing market trends, market players and their leading pipeline candidates. This chapter also covers the mergers and acquisitions and any other collaborations or partnerships that happened during the evaluation period of this report that are expected to shape the industry.

Factors such as strengths, weaknesses, threats and opportunities that are expected to play a role in the microbiome therapeutics market are evaluated in detail.

Excluded from this report are the markets for prebiotics and probiotics labeled as nutritional or dietary supplements. Prebiotics and probiotics, if included, only pertain to when used in the context of microbiome therapy.

Report Includes:

  • 32 data tables and 47 additional tables
  • An in-depth overview of the global microbiome therapeutics market
  • Analyses of the global market trends, with data corresponding to market size for 2021-2025, and projections of compound annual growth rates (CAGRs) through 2026
  • Latest information on market drivers and opportunities, challenges and restraints, technological developments, and regulatory updates, along with their impact on the stakeholders in this market
  • Evaluation of market potential for microbiome therapeutics market, their market share analysis on the basis of product types, applications, and regions
  • Highlights of this innovation driven microbiome therapeutics market covering current trends, disease areas of application, clinical trials and their stages, and new developments
  • Impact of COVID-19 pandemic on the global economy and delay in the clinical trial activity and financial effects on the overall growth of this market
  • Competitive landscape of this market featuring leading biopharmaceutical companies, their products pipeline and company share analysis
  • Key merger and acquisition deals, collaborations and partnerships, licensing and manufacturing agreements, and other notable investment strategies within this market
  • Patent review and deep-dive of the issued patents on the basis of categories such as type, year, disease type, company, country, and assignee
  • Profile description of the major market participants, including Azitra Inc., Evelo Biosciences, LNC Therapeutics, Second Genome and Vedanta Biosciences Inc.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

  • Key Highlights

Chapter 3: Market and Technology Background

  • The Human Microbiome
    • The Different Microbiomes in Humans
    • Microbiome and Human Health and Disease
    • Technologies Aiding Microbiome Research
    • Microbiome Research Projects
  • Microbiome Therapeutics
    • Strategies for Development of Microbiome Therapeutics
    • Microbiome Therapeutics Disease Areas
    • Regulatory Landscape for Microbiome Therapeutics

Chapter 4: Market Breakdown by Technology Type

  • Market by Microbiome Strategy Type
    • Market Overview
    • Additive Microbiome Therapeutics
    • Modulatory Microbiome Therapeutics
    • Subtractive Microbiome Therapeutics

Chapter 5: Market Breakdown by Application

  • Market by Disease Type
    • Market Overview
    • Market Revenue
    • Market Shares
    • Infections
    • Gastrointestinal (GIT) Diseases
    • Metabolic Diseases
    • Cancer
    • Gut-Brain Axis Diseases
    • Other Diseases
  • Market by Region
    • Market Shares

Chapter 6: Industry Structure

  • Investment in Microbiome Therapeutics
    • Public Funding Initiatives
    • Private Funding Initiatives
  • Collaborations and Partnerships
  • Licensing and Manufacturing Agreements
  • Mergers and Acquisitions
  • Leading Market Players in Microbiome Therapeutics Market
    • Leading Market Players in Additive Microbiome Therapeutics Market
    • Leading Market Players in Modulatory Microbiome Therapeutics Market
    • Leading Market Players in Subtractive Microbiome Therapeutics Market
  • BCC Research Select Insights from Industry Leaders

Chapter 7: Patent Analysis

  • Patent Analysis
    • Patents by Year
    • Patents by Type
    • Patents by Disease Type
    • Patents by Company
    • Patents by Country
    • Patents by Assignee

Chapter 8: Clinical Trial Analysis

  • Clinical Trial Analysis by Disease Category
    • Share of Clinical Trials
  • Clinical Trial Analysis by Treatment Strategy
    • Share of Clinical Trials
  • Clinical Trial Analysis by Company
    • Share of Clinical Trials
  • Microbiome Therapeutics in Discovery and Preclinical Development
  • Microbiome Therapeutics Clinical Trials in Phase 3

Chapter 9: Analysis of Market Opportunities

  • SWOT Analysis
    • Strengths of Microbiome Therapeutics Market
    • Challenges for Microbiome Therapeutics Market
    • Opportunities for Microbiome Therapeutics Market
    • Threats to the Microbiome Therapeutics Market

Chapter 10: Company Profiles

  • 4D PHARMA
  • AO BIOME LLC
  • ASSEMBLY BIOSCIENCES INC.
  • ARMATA PHARMACEUTICALS
  • AZITRA INC.
  • BIOMICA
  • BIOMX
  • CHAIN BIOTECHNOLOGY LTD.
  • ELIGO BIOSCIENCE SAS
  • ENTEROME SA
  • EVELO BIOSCIENCES
  • FINCH THERAPEUTICS GROUP INC.
  • INTRALYTIX INC.
  • KALEIDO BIOSCIENCES
  • KINTAI THERAPEUTICS INC.
  • LNC THERAPEUTICS INC.
  • MAAT PHARMA
  • OSEL INC.
  • PYLUM BIOSCIENES INC.
  • QUORUM INNOVATIONS LLC
  • REBIOTIX INC. (ACQUIRED BY FERRING PHARMACEUTICALS)
  • SECOND GENOME
  • SERES THERAPEUTICS INC.
  • SFA THERAPEUTICS INC.
  • SYNLOGIC
  • SYNTHETIC BIOLOGICS INC.
  • VEDANTA BIOSCIENCES INC.

Chapter 11: Appendix: Acronyms

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.